OCUP vs. CLRB, IVA, VERU, IXHL, TRVI, GLSI, LFCR, ABEO, RIGL, and ALIM
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Cellectar Biosciences (CLRB), Inventiva (IVA), Veru (VERU), Incannex Healthcare (IXHL), Trevi Therapeutics (TRVI), Greenwich LifeSciences (GLSI), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Rigel Pharmaceuticals (RIGL), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Ocuphire Pharma currently has a consensus target price of $18.75, suggesting a potential upside of 983.88%. Cellectar Biosciences has a consensus target price of $20.00, suggesting a potential upside of 538.98%. Given Ocuphire Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocuphire Pharma is more favorable than Cellectar Biosciences.
Cellectar Biosciences received 206 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 68.00% of users gave Ocuphire Pharma an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by company insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cellectar Biosciences had 3 more articles in the media than Ocuphire Pharma. MarketBeat recorded 6 mentions for Cellectar Biosciences and 3 mentions for Ocuphire Pharma. Ocuphire Pharma's average media sentiment score of 1.59 beat Cellectar Biosciences' score of 1.18 indicating that Ocuphire Pharma is being referred to more favorably in the media.
Cellectar Biosciences has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -59.44%. Ocuphire Pharma's return on equity of -24.57% beat Cellectar Biosciences' return on equity.
Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Ocuphire Pharma has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Summary
Ocuphire Pharma beats Cellectar Biosciences on 12 of the 18 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
